Last reviewed · How we verify
Systemic mast cell disease
Approved treatments
- Intal · Pfizer
- Cromoglicate · LEO Pharma
- Gleevec · M.D. Anderson Cancer Center
- Aciphex · University of Utah
- Tagamet
- Aciphex · Waylis
Aciphex works by irreversibly inhibiting the potassium-transporting ATPase enzyme in the stomach lining, reducing acid production. - Gleevec · Novartis
Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation. - Ayvakit · Blueprint Medicines
Ayvakit works by blocking the activity of the PDGFRA protein, which is involved in the growth and spread of cancer cells. - Rabeprazol · Janssen-Cilag, S.A.
- Cromoglycate · Vishwajit Nimgaonkar, MD PhD
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Systemic mast cell disease patent landscape — cliff calendar, originator estates, attackable patents
- Systemic mast cell disease treatment landscape brief
- Systemic mast cell disease treatment updates RSS
Frequently asked questions about Systemic mast cell disease
What drugs treat Systemic mast cell disease?
Tracked treatments include Intal, Cromoglicate, Gleevec, Aciphex, Tagamet, Ayvakit, Rabeprazol, Cromoglycate.
What is the treatment for Systemic mast cell disease?
Standard treatment for Systemic mast cell disease includes Intal, Cromoglicate, Gleevec, Aciphex, Tagamet. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Systemic mast cell disease patent cliff · Systemic mast cell disease CI report
- Treatment: Intal · Pfizer
- Treatment: Cromoglicate · LEO Pharma
- Treatment: Gleevec · M.D. Anderson Cancer Center
- Treatment: Aciphex · University of Utah
- Treatment: Tagamet
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing